News Introduction

Vinpocetine(CAS 42971-09-5) for injection

Date : 2016/10/17 11:38:47

Vinpocetine(CAS 42971-09-5) for injection: a vasodilator.

Muscle aminopeptidase for injection: cerebrovascular accident caused by paralysis; peripheral neuropathy caused by muscle atrophy.

Meclofenoxate Hydrochloride: traumatic coma, alcoholism, neonatal hypoxia, enuresis in children.

Buflomedil hydrochloride: ① peripheral vascular disease ② chronic cerebrovascular insufficiency caused by symptoms: dizziness, tinnitus, mental retardation, memory or attention, orientation disorders.


Over the past year, injection can be called each other varieties of chemical drugs in the "new force", the huge number of species concentration is breathtaking! Analysis of this declaration is one of the main reasons for the situation in accordance with China's current registration laws and regulations, "the same active ingredient made of small water injection, powder injection, the infusion between the change of drug registration applications, routes and methods of administration, Such as the original drug-based formulations, and can generally avoid clinical research, "so the research and development of such species may have a short cycle, low-cost characteristics, by a large number of investors" favor. " However, R & D enthusiasm does not mean that the rising level of R & D, from the current review of the situation can be seen, the size of each needle to change the rate of hair replacement rate is relatively high (hair loss rate of 60%), and the problems are More concentrated. To some extent, this shows that some R & D in the development of such varieties, there is no combination of drug characteristics and clinical use of its own characteristics of in-depth study.

In addition, the repeated reporting of the situation is very serious, according to incomplete statistics, to declare the varieties of acetylglutamine has 35, 36 vinpocetine(CAS 42971-09-5), troxerutin 65, more than 50 diacetyl ethylenediamine ethylenediamine, Chuanhuning 46 Family. This reflects to a certain extent the applicant in the development of new products, the clinical and market demand for drugs is not enough, blind development may lead to vicious competition in the market and research and development, production of a huge waste of resources.